申请人:Merck Sharp & Dohme Ltd.
公开号:US05994374A1
公开(公告)日:1999-11-30
A class of 1-[3-(1H-indol-3-yl)propyl]-4-benzyl-1,2,5,6-tetrahydropyridine derivatives, substituted at the 5-position of the indole nucleus by a 1,2,4-triazol-4-yl moiety, and on the methylene linkage of the benzyl moiety by an alkyl, alkoxy, or alkoxy-alkoxy substituent, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype while possessing at least a 10-fold selective affinity for the 5HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype. They are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D.alpha. receptors is indicated, and are expected to have fewer undesirable cardiovascular and other side effects.
一类1-[3-(1H-吲哚-3-基)丙基]-4-苄基-1,2,5,6-四氢吡啶衍生物,其在吲哚核的5位被1,2,4-三唑-4-基取代,并且在苄基的亚甲基连接处被烷基、烷氧基或烷氧基-烷氧基取代,是5-HT.sub.1-样受体的选择性激动剂,是人类5-HT.sub.1D.alpha.受体亚型的有效激动剂,同时相对于5-HT.sub.1D.beta.亚型具有至少10倍的选择性亲和力。因此,它们在治疗和/或预防临床疾病方面具有用途,特别是偏头痛及相关疾病,这些疾病需要5-HT.sub.1D.alpha.受体的亚型选择性激动剂,并且预计它们会具有较少的不良心血管和其他副作用。